Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Celebrex Reissue Patent Reawakens Generic Litigation

Executive Summary

Pfizer sues five generic firms alleging their celecoxib ANDAs infringe a reissued method-of-use patent, which protects the blockbuster COX-2 inhibitor until December 2015, 18 months longer than had been expected.

You may also be interested in...



Generic Celebrex Dispute Shows Hatch-Waxman’s Legal Wrath

Ongoing battle over 180-day exclusivity shows just how complex life under the 1984 amendments to the FD&C Act can get.

Pfizer’s Celebrex Could Face Generic At-Risk Launches In May

Pfizer had hoped to gain an extra 18 months of patent protection with a reissue patent granted last year but a district court ruled the method of use patent is invalid.

Celebrex Generics: Will Any Qualify For 180-Day Market Exclusivity?

Last patent covering Pfizer’s pain drug is a reissue of an earlier patent on which 180-day exclusivity has already been triggered; FDA has previously declined to award exclusivity to such patents.

Related Content

Topics

Related Companies

UsernamePublicRestriction

Register

PS055179

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel